No photo of Shuo Ma

View Scopus Profile

Shuo Ma

  • 2040 Citations
19992024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Certifications and Licenses

Medical Oncology
Hematology
Internal Medicine

Training Experience

2005Residency, Resurrection Hospitals
2008Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

PhD, Northwestern University Feinberg School of Medicine

… → 2000

MD, Beijing Medical University

… → 1994

Keywords

  • Biologic Therapies
  • Blood Cancer (leukemia and lymphomas)
  • Chronic Lymphocytic Leukemia
  • Hematology
  • Non-Hodgkin's Lymphoma
  • Oncology

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Dyneins Medicine & Life Sciences
Dictyostelium Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Signal Transduction Medicine & Life Sciences
Leukocytes Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2007 2024

Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL

Ma, S.

TG Therapeutics, Inc.

4/12/19 → 4/12/24

Project: Research project

Prot #BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/8/19 → 2/8/22

Project: Research project

Prot #BGB-3111-304: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/5/19 → 2/5/22

Project: Research project

Prot #017004: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Ma, S.

DrugDev Inc., Juno Therapeutics, Inc.

1/18/19 → 1/18/22

Project: Research project

Prot #INCB50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

Ma, S.

Covance Inc., Incyte Corporation

1/24/18 → 1/24/21

Project: Research project

Research Output 1999 2019

1 Citation (Scopus)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 othersMato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner, N., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

Research output: Contribution to journal › Article

B-Cell Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma
Guidelines

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Ma, S., Tausch, E., Cramer, P., Huang, J. & 4 othersMitra, S., Hallek, M., O'Brien, S. M. & Stilgenbauer, S., Jun 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 16, p. 1391-1402 12 p.

Research output: Contribution to journal › Article

Open Access
B-Cell Chronic Lymphocytic Leukemia
Placebos
Disease-Free Survival
Safety
idelalisib
1 Citation (Scopus)

Risk factors for the development of atrial fibrillation on ibrutinib treatment

Lentz, R., Feinglass, J. M., Ma, S. & Akhter, N., Jan 1 2019, In : Leukemia and Lymphoma.

Research output: Contribution to journal › Article

Atrial Fibrillation
B-Cell Chronic Lymphocytic Leukemia
Electrocardiography
Therapeutics
Heart Diseases

Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?

Ma, S. & Platanias, L. C., Jul 24 2018, In : Expert Opinion on Pharmacotherapy. 19, 11, p. 1171-1175 5 p.

Research output: Contribution to journal › Editorial

B-Cell Chronic Lymphocytic Leukemia
Morbidity
Drug Therapy
Mortality
3 Citations (Scopus)

Frontline Therapy of CLL: Evolving Treatment Paradigm

Boddy, C. S. & Ma, S., Apr 1 2018, In : Current Hematologic Malignancy Reports. 13, 2, p. 69-77 9 p.

Research output: Contribution to journal › Review article

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Immunoglobulin Heavy Chain Genes
Phase III Clinical Trials
Mutation